137 related articles for article (PubMed ID: 1820883)
41. Bioavailability of erythromycin acistrate from hard gelatin capsules containing sodium bicarbonate.
Marvola M; Nykänen S; Nokelainen M
Pharm Res; 1991 Aug; 8(8):1056-8. PubMed ID: 1656422
[TBL] [Abstract][Full Text] [Related]
42. Antacid activity of calcium carbonate and hydrotalcite tablets. Comparison between in vitro evaluation using the "artificial stomach-duodenum" model and in vivo pH-metry in healthy volunteers.
Vatier J; Ramdani A; Vitré MT; Mignon M
Arzneimittelforschung; 1994 Apr; 44(4):514-8. PubMed ID: 8011006
[TBL] [Abstract][Full Text] [Related]
43. Differing disintegration and dissolution rates, pharmacokinetic profiles and gastrointestinal tolerability of over the counter ibuprofen formulations.
Bjarnason I; Sancak O; Crossley A; Penrose A; Lanas A
J Pharm Pharmacol; 2018 Feb; 70(2):223-233. PubMed ID: 29238984
[TBL] [Abstract][Full Text] [Related]
44. Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.
Frost RW; Lasseter KC; Noe AJ; Shamblen EC; Lettieri JT
Antimicrob Agents Chemother; 1992 Apr; 36(4):830-2. PubMed ID: 1503446
[TBL] [Abstract][Full Text] [Related]
45. Rapidly absorbed solid oral formulations of ibuprofen using water-soluble gelatin.
Imai T; Kimura S; Iijima T; Miyoshi T; Ueno M; Otagiri M
J Pharm Pharmacol; 1990 Sep; 42(9):615-9. PubMed ID: 1981899
[TBL] [Abstract][Full Text] [Related]
46. Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics.
Akerele JO; Okhamafe AO
J Antimicrob Chemother; 1991 Jul; 28(1):87-94. PubMed ID: 1663108
[TBL] [Abstract][Full Text] [Related]
47. Relative bioavailability of commercially available ibuprofen oral dosage forms in humans.
Gillespie WR; DiSanto AR; Monovich RE; Albert KS
J Pharm Sci; 1982 Sep; 71(9):1034-8. PubMed ID: 7131270
[TBL] [Abstract][Full Text] [Related]
48. The bioavailability of flufenamic acid from aluminum flufenamate tablet and flufenamic acid capsule, and the influence of food and aluminum hydroxide gel.
Kaniwa N; Ogata H; Aoyagi N; Ejima A
J Pharmacobiodyn; 1982 Mar; 5(3):187-92. PubMed ID: 7097486
[TBL] [Abstract][Full Text] [Related]
49. Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humans-Part 1: Fasted State Conditions.
Bermejo M; Paixão P; Hens B; Tsume Y; Koenigsknecht MJ; Baker JR; Hasler WL; Lionberger R; Fan J; Dickens J; Shedden K; Wen B; Wysocki J; Löbenberg R; Lee A; Frances A; Amidon GE; Yu A; Salehi N; Talattof A; Benninghoff G; Sun D; Kuminek G; Cavanagh KL; Rodríguez-Hornedo N; Amidon GL
Mol Pharm; 2018 Dec; 15(12):5454-5467. PubMed ID: 30372084
[TBL] [Abstract][Full Text] [Related]
50. The in vitro bioavailability of various drugs formulated as hard gelatin capsules.
Newton JM; Razzo FN
J Pharm Pharmacol; 1977 Apr; 29(4):205-8. PubMed ID: 17668
[TBL] [Abstract][Full Text] [Related]
51. Accelerated oral absorption of gliclazide in human subjects from a soft gelatin capsule containing a PEG 400 suspension of gliclazide.
Hong SS; Lee SH; Lee YJ; Chung SJ; Lee MH; Shim CK
J Control Release; 1998 Feb; 51(2-3):185-92. PubMed ID: 9685916
[TBL] [Abstract][Full Text] [Related]
52. Development of level A, B and C in vitro-in vivo correlations for modified-release levosimendan capsules.
Kortejärvi H; Mikkola J; Bäckman M; Antila S; Marvola M
Int J Pharm; 2002 Jul; 241(1):87-95. PubMed ID: 12086724
[TBL] [Abstract][Full Text] [Related]
53. Novel approach for determination of correlation between in vivo and in vitro dissolution using the optimization technique.
Ishii K; Saitou Y; Yamada R; Itai S; Nemoto M
Chem Pharm Bull (Tokyo); 1996 Aug; 44(8):1550-5. PubMed ID: 8795273
[TBL] [Abstract][Full Text] [Related]
54. Absorption kinetics of rectally and orally administered ibuprofen.
Eller MG; Wright C; Della-Coletta AA
Biopharm Drug Dispos; 1989; 10(3):269-78. PubMed ID: 2720131
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of low-molecular gelatin as a pharmaceutical additive for rapidly absorbed oral dosage formulation.
Kimura S; Imai T; Otagiri M
Chem Pharm Bull (Tokyo); 1991 May; 39(5):1328-9. PubMed ID: 1914011
[TBL] [Abstract][Full Text] [Related]
56. The influence of additives on the presentation of a drug in hard gelatin capsules.
Newton JM; Razzo FN
J Pharm Pharmacol; 1977 May; 29(5):294-7. PubMed ID: 17694
[TBL] [Abstract][Full Text] [Related]
57. Influence of enzymes and surfactants on the disintegration behavior of cross-linked hard gelatin capsules during dissolution.
Pennings FH; Kwee BL; Vromans H
Drug Dev Ind Pharm; 2006 Jan; 32(1):33-7. PubMed ID: 16455602
[TBL] [Abstract][Full Text] [Related]
58. Influence of Polymer Type on the Physical Properties and Release Profile of Papaverine Hydrochloride From Hard Gelatin Capsules.
Polski A; Iwaniak K; Kasperek R; Modrzewska J; Sobótka-Polska K; Sławińska K; Poleszak E
Polim Med; 2015; 45(2):51-5. PubMed ID: 26994886
[TBL] [Abstract][Full Text] [Related]
59. The effect of gelatin cross-linking on the bioequivalence of hard and soft gelatin acetaminophen capsules.
Meyer MC; Straughn AB; Mhatre RM; Hussain A; Shah VP; Bottom CB; Cole ET; Lesko LL; Mallinowski H; Williams RL
Pharm Res; 2000 Aug; 17(8):962-6. PubMed ID: 11028942
[TBL] [Abstract][Full Text] [Related]
60. Improving the oral bioavailability of sulpiride by sodium oleate in rabbits.
Naasani I; Kohri N; Iseki K; Miyazaki K
J Pharm Pharmacol; 1995 Jun; 47(6):469-73. PubMed ID: 7674129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
